P098: Contralateral metachronous breast cancer - Risk of metastasis and subsequent treatment choice following previous breast conservation surgery

Abstract

Introduction: The incidence of contralateral metachronous breast cancer ranges from 0.5% to 0.75% per annum. Access to effective adjuvant therapies has led to a positive reduction in this incidence, yet data from the USA show a 150% increase in contralateral risk reducing mastectomies. This contrasts with surgical practice in the UK where breast conservation (BCS) rates remain high. When faced with a contralateral metachronous cancer, and in the absence of a known gene mutation, do patients in the UK have a treatment preference?